Acute Myeloid Leukemia (AML)

Found 468 clinical trials|View Analysis

Sort by:

Need a comprehensive medical report on "Acute Myeloid Leukemia (AML)"?

Analyze the latest clinical research and treatment options

Summarize scientific findings from medical journals

Trial to Find and Investigate a Safe Dose of F16IL2 and BI 836858 in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

Phase 1

Completed

Conditions: Acute Myeloid Leukemia (AML) Relapse

Interventions: Drug: F16IL2
Drug: BI 836858

First Posted Date: 2017-07-02

Last Posted Date: 2022-04-20

Lead Sponsor: Philogen S.p.A.

Target Recruit Count: 15

Registration Number: NCT03207191

Locations: 🇩🇪
University Medical Center Freiburg, Freiburg, Germany
🇩🇪
Münster University Hospital, Münster, Germany

IDH1/IDH2 Mutation Frequency in Acute Myeloblastic Patients

Conditions: Acute Myeloid Leukemia (AML)

First Posted Date: 2017-07-02

Last Posted Date: 2017-07-02

Lead Sponsor: Hospital General de Mexico

Target Recruit Count: 100

Registration Number: NCT03204838

Locations: 🇲🇽
Ciudad de Mexico, Mexico City, Mexico

Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)

Recruiting

Conditions: Acute Myeloid Leukemia (AML)

First Posted Date: 2017-06-16

Last Posted Date: 2024-04-18

Lead Sponsor: Technische Universität Dresden

Target Recruit Count: 15000

Registration Number: NCT03188874

Locations: 🇩🇪
Klinikum Mittelbaden, Baden-Baden, Baden-Württemberg, Germany
🇩🇪
Universtitätsklinikum Heidelberg, Heidelberg, Baden-Württemberg, Germany
🇩🇪
Klinikum Mannheim GmbH, Mannheim, Baden-Württemberg, Germany

and more 48 locations

A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation

Phase 3

Active, not recruiting

Conditions: AML With FLT3 Mutation

Interventions: Drug: Gilteritinib
Drug: Cytarabine
Drug: Mitoxantrone
Drug: Etoposide
Drug: G-CSF
Drug: Fludarabine

First Posted Date: 2017-06-09

Last Posted Date: 2025-08-01

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 276

Registration Number: NCT03182244

Locations: 🇨🇳
Site CN130, Guiyang City, China
🇨🇳
Site CN107, Hangzhou, China
🇨🇳
Site CN118, Hefei, China

and more 46 locations

Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation

Phase 3

Active, not recruiting

Conditions: Newly Diagnosed Acute Myeloid Leukemia (AML)
Untreated AML
AML Arising From Myelodysplastic Syndrome (MDS)
Leukemia, Myeloid, Acute

Interventions: Drug: AG-120
Drug: Placebo
Drug: Azacitidine

First Posted Date: 2017-06-01

Last Posted Date: 2024-08-20

Lead Sponsor: Institut de Recherches Internationales Servier

Target Recruit Count: 146

Registration Number: NCT03173248

Locations: 🇮🇱
Shamir Medical Center Assaf Harofeh, Tzrifin, Israel
🇺🇸
Norton Cancer Institute - Suburban, Louisville, Kentucky, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 87 locations

Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients with Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

Phase 2

Terminated

Conditions: Myelodysplastic Syndrome
Acute Myeloid Leukemia

Interventions: Drug: Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen
Drug: Cladribine and Cytarabine (CLLDAC) Regimen

First Posted Date: 2017-05-11

Last Posted Date: 2025-03-26

Lead Sponsor: Medical College of Wisconsin

Target Recruit Count: 53

Registration Number: NCT03150004

Locations: 🇺🇸
Froedtert & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States

BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML)

Phase 1

Completed

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: BAY1436032

First Posted Date: 2017-04-25

Last Posted Date: 2019-05-14

Lead Sponsor: Bayer

Target Recruit Count: 27

Registration Number: NCT03127735

Locations: 🇺🇸
Montefiore Medical Center, Bronx, New York, United States
🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
🇺🇸
Mount Sinai Medical Center, New York, New York, United States

and more 10 locations

A Phase Ib Study of CT053PTSA in Relapsed / Refractory Acute Myeloid Leukemia (AML)

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia (AML)

Interventions: Drug: CT053PTSA

First Posted Date: 2017-04-24

Last Posted Date: 2021-03-24

Lead Sponsor: Sunshine Lake Pharma Co., Ltd.

Target Recruit Count: 12

Registration Number: NCT03125876

Locations: 🇨🇳
Hospital of Blood Disease, Chinese Academy of Medical Sciences, Tianjin, China

Expanded Access to Venetoclax

Conditions: Chronic Lymphocytic Leukemia (CLL)
Multiple Myeloma
Acute Myeloid Leukemia (AML)
Non-Hodgkin's Lymphoma
Acute Lymphoblastic Leukemia (ALL)
Amyloidosis
Plasma Cell Leukemia

First Posted Date: 2017-04-21

Last Posted Date: 2025-04-04

Lead Sponsor: AbbVie

Registration Number: NCT03123029

An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML)

Conditions: FLT3-mutated Acute Myeloid Leukemia

First Posted Date: 2017-04-14

Last Posted Date: 2019-10-15

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT03114228

Locations: 🇨🇦
Novartis Investigative Site, Montreal, Quebec, Canada

AI-Powered Research

Premium Access

Trial to Find and Investigate a Safe Dose of F16IL2 and BI 836858 in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

IDH1/IDH2 Mutation Frequency in Acute Myeloblastic Patients

Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)

A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation

Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation

Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients with Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML)

A Phase Ib Study of CT053PTSA in Relapsed / Refractory Acute Myeloid Leukemia (AML)

Expanded Access to Venetoclax

An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML)

MedPath

Product

Company

Legal